Long-term follow-up of a randomized trial of fludarabine–mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
Authors:
- P. ColombatPCP. Colombat
- H. MaisonneuveHMH. Maisonneuve
- C. BerthouCBC. Berthou
- R. GressinRGR. Gressin
- M.-C. RousseletMRM.-C. Rousselet
Open Access
- 2 February 2005
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 16 (3) , 466-472
Abstract
Background: This randomized study compared the efficacy and safety of fludarabine–mitoxantrone (FM) with mini-CHVP (cyclophosphamide, doxorubicin, vindesine, prednisone) in elderly patients with advanced, low-grade non-Hodgkin's lymphoma. Patients and methods: End points were remission rates [overall response (OR) and complete response (CR)], failure-free survival (FFS), survival and toxicity. One hundred and fifty-five patients were randomized, 144 were evaluable for safety and 142 for response. Each treatment arm was given as six monthly cycles, followed by three bimonthly cycles. FM comprised fludarabine (20 mg/m2 i.v.), days 1–5, plus mitoxantrone (10 mg/m2 i.v.), day 1. CHVP cycles comprised cyclophosphamide (750 mg/m2 i.v. infusion), doxorubicin (25 mg/m2 i.v.) and vindesine (3 mg/m2 i.v.) on day 1, and prednisone (50 mg/m2) on days 1–5. Results: FM therapy resulted in superior remission rates (OR 81% versus 64%, CR 49% versus 17%; P=0.0004). Median FFS for FM patients was 36 months, compared with 19 months for CHVP patients, and has not yet been reached for early CR patients at 53 months. Treatment arm was the major risk factor influencing survival. Both treatments were well tolerated, with only few infectious complications. Conclusion: FM was more effective than CHVP in achieving OR and CR, and favorably affected the outcome.Keywords
This publication has 22 references indexed in Scilit:
- Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B‐ and T‐cell lymphoid malignancies in Chinese patientsBritish Journal of Haematology, 2004
- Intensive therapies in follicular non-Hodgkin lymphomasBlood, 2002
- Mitoxantrone and Fludarabine in the Treatment of Patients with Non-Hodgkin's Lymphoma Failing Primary Therapy with a Doxorubicin-or Mitoxantrone-Containing RegimenLeukemia & Lymphoma, 2001
- A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphomaAnnals of Oncology, 2000
- Phase I Study of Fludarabine Plus Cyclophosphamide in Patients With Previously Untreated Low-Grade Lymphoma: Results and and Long-Term Follow-Up—A Report From the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2000
- Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.Journal of Clinical Oncology, 1998
- Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage 111-IV patientsAnnals of Oncology, 1997
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]Blood, 1994
- Fludarabine in the Management of Malignant LymphomasDrugs, 1994
- Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphomaAnnals of Oncology, 1993